Katagiri Daisuke, Kikuchi Kan
Department of Nephrology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
Division of Nephrology, Shimoochiai Clinic, Tokyo 161-0033, Japan.
J Clin Med. 2023 Jan 20;12(3):838. doi: 10.3390/jcm12030838.
Patients with coronavirus disease 2019 (COVID-19) undergoing maintenance hemodialysis have a poor prognosis and limited treatment options.
This paper outlines the impact of COVID-19, its treatment, and the efficacy of vaccines in Japanese patients undergoing hemodialysis with a review of the literature.
Patients undergoing dialysis in dialysis facilities are at greater risk of exposure to severe acute respiratory syndrome coronavirus 2 than the general population due to limited isolation capabilities. Therefore, vaccines are expected to be effective for patients undergoing dialysis. In addition, effective use of available medications is important because treatment options are limited.
Efforts should be made to prevent the spread of the infection to high-risk patients undergoing dialysis while ensuring the effective use of vaccines.
接受维持性血液透析的2019冠状病毒病(COVID-19)患者预后较差且治疗选择有限。
本文通过文献综述概述了COVID-19对日本接受血液透析患者的影响、其治疗方法以及疫苗的疗效。
由于隔离能力有限,透析设施中的透析患者比普通人群面临更高的感染严重急性呼吸综合征冠状病毒2的风险。因此,疫苗有望对透析患者有效。此外,由于治疗选择有限,有效使用现有药物很重要。
应努力防止感染传播给接受透析的高危患者,同时确保疫苗的有效使用。